August 20 – 21, 2019

2018 Speakers

Expand/Collapse

Komathi Stem
Founder & Chief Executive Officer
monARC Bionetworks

Day One

Tuesday 21 August, 2018

15.15 | Transforming IPF Clinical Trials Through Direct Patient Engagement

John Stauffer
Senior Medical Director
Genentech

Day One

Tuesday 21 August, 2018

14.15 | A Closer Look at FVC

Yvon Jule
Chief Scientific Officer
Biocellvia

Day One

Tuesday 21 August, 2018

12.30 | Be Better then Ashcroft Scoring: Quantitative, Reproducible Assessment of IPF by Automated Digital Image Analysis

Neeraj Vij
Program Director, Clinical Development
4Dx

Day One

Tuesday 21 August, 2018

11.30 | Introduction to 4Dx Technology

Andreas Fouras
Chief Executive Officer
4Dx

Day Two

Wednesday 22 August, 2018

12.00 | Application of 4Dx Technology to IPF Research

David Schwartz
Professor of Medicine & Immunology
University of Colorado-Denver

Day One

Tuesday 21 August, 2018

17.00 | Panel Discussion: Precision Medicine in IPF - Using Genetics to Inform Patient Stratification Decisions for Clinical Trials

16.30 | Genetic & Genomic Considerations in IPF Clinical Trials

Fernando Martinez
Chief, Pulmonary & Critical Care Medicine
Weill Cornell Medical College

Day One

Tuesday 21 August, 2018

17.45 | Chair’s Closing Remarks

17.00 | Panel Discussion: Precision Medicine in IPF - Using Genetics to Inform Patient Stratification Decisions for Clinical Trials

09.00 | Keynote: IPF: Where are we now?

08.50 | Chair’s Opening Remarks

Day Two

Wednesday 22 August, 2018

17.00 | Chair’s Closing Remarks

08.20 | Chair’s Opening Remarks

Gerald Nabozny
Executive Director Inflammation, Immunology & Respiratory Disease Research
Boehringer Ingelheim

Day One

Tuesday 21 August, 2018

09.30 | Beyond Bleomycin: The Nintedanib Experience

Jan De Backer
Chief Executive Officer
Fluidda

Day One

Tuesday 21 August, 2018

13.45 | Regional Disease Progression & Quantification of Interstitial Lung Diseases Using Functional Respiratory Imaging

Joe Arron
Senior Director, Immunology Research
Genentech

Day Two

Wednesday 22 August, 2018

14.30 | Panel Discussion: Assessing the Current Drug Landscape to Understand Combinations as Successful Treatment Options Within IPF

13.30 | Lessons Learnt from Combination Therapies with Pirfenidone

John Moran
Chief Medical Officer
Prometic Biosciences

Day One

Tuesday 21 August, 2018

14.45 | IPF: An Orphan Disease with Successful Phase 3 Trials!

Day Two

Wednesday 22 August, 2018

14.30 | Panel Discussion: Assessing the Current Drug Landscape to Understand Combinations as Successful Treatment Options Within IPF

John Ryan
Executive Vice President & Chief Medical Officer
Kadmon

Day One

Tuesday 21 August, 2018

16.00 | Rho-Associated Coiled-Coil Kinase 2 (ROCK2) Inhibition in IPF

Jonathan Kropski
Assistant Professor of Medicine
Vanderbilt University Medical Center

Workshop B

Monday, August 20 2018

13.00 | Using Genetic Information to Personalize Therapeutic Approaches for IPF

Majd Mouded
Medical Director
Biogen

Day One

Tuesday 21 August, 2018

12.00 | Leveraging Biomarker Data for Dose Selection

Mary Salvatore
Associate Professor of Radiology
Mount Sinai Medical Center

Workshop A

Monday, August 20 2018

09.00 | Adding Radiology to the Pulmonary Fibrosis Equation

Ulrike Muscha Steckelings
Chief Scientific Officer
Vicore Pharma

Day Two

Wednesday 22 August, 2018

15.30 | Targeting the Angiotensin AT2-receptor for the Treatment of Orphan Fibrotic Diseases

Rick Jack
President, Chief Operations Officer & Chief Scientific Officer
Promedior

Day Two

Wednesday 22 August, 2018

16.30 | Evaluation of Pentraxin-2 (PRM-151) in IPF Clinical Trial Settings

Rusty Montgomery
Director Research
miRagen Therapeutics

Day Two

Wednesday 22 August, 2018

09.30 | Innovative RNA Based Therapeutics as a Modality for the Effective Treatment of Multiple Fibrotic Conditions

Eduard Gorina
Executive Director Clinical Development Fibrosis Program
FibroGen

Day Two

Wednesday 22 August, 2018

14.00 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety & Efficacy of Pamrevlumab (FG-3019) in Patients with IPF

14.30 | Panel Discussion: Assessing the Current Drug Landscape to Understand Combinations as Successful Treatment Options Within IPF

Timothy Blackwell
Professor of Medicine
Vanderbilt University Medical Center

Workshop B

Monday, August 20 2018

13.00 | Using Genetic Information to Personalize Therapeutic Approaches for IPF

Day One

Tuesday 21 August, 2018

17.00 | Panel Discussion: Precision Medicine in IPF - Using Genetics to Inform Patient Stratification Decisions for Clinical Trials

Sonya Zablodoff
Senior Director of Pharmacology
Nitto BioPharma

Day Two

Wednesday 22 August, 2018

10.30 | Developmental Program Identifying siRNA HSP47 as a New Therapeutic Strategy for IPF – Comprehensive Model Validation & Therapeutic Evaluation

Anne Phelan
Senior Vice President & Head of Discovery Research
Mission Therapeutics

Day Two

Wednesday 22 August, 2018

16.00 | UCHL1 – A Deubiquitylating Enzyme with Fundamental Roles in the Regulation of Pro-Fibrotic Signalling Pathways

Brian Windsor
Chief Executive Officer
Lung Therapeutics

Day Two

Wednesday 22 August, 2018

09.00 | Restoring Balance in IPF: Development of a Compound Targeting Both Epithelial Cell Survival as well as Myofibroblast Destruction for Improved Therapeutic Response

Cory Hogaboam
Professor of Medicine
Ceders-Sinai Medical Center

Day Two

Wednesday 22 August, 2018

08.30 | Translational Modeling of Profibrotic & Aberrant Regenerative Mechanisms in IPF